IL-NIELSENIQ
21.7.2022 13:02:04 CEST | Business Wire | Press release
NielsenIQ is pleased to announce the 2022 recipients of the seventh annual NielsenIQ BASES Design Impact Awards for the consumer-packaged goods (CPG) industry. The global competition recognizes and celebrates best-in-class package redesigns, and the business impacts they make for their companies. This year’s winners include brands that delivered innovative and creative packaging with design concepts that reflected brand vision while supporting the shopper journey.
Sixty brands submitted package redesigns and the NielsenIQ BASES team used the company’s proprietary Retail Measurement Sales (RMS) data to identify which brands demonstrated an increase in sales after the launch of the updated package designs. In addition to evaluating RMS data, NielsenIQ conducted a behavioral survey of 15,000 shoppers to assess individual entries across the shopper journey. Each product was evaluated to determine if it presented a visually appealing, easily identifiable package that allowed consumers to find the product on shelves and engage them to purchase the item. The results unveiled 10 winners across various CPG categories with excellent designs and a measurable increase in sales.
“Our team is thrilled to support and promote inspired brands who deliver fresh, beautifully designed packages that stimulate brand growth and financial successes,” said Andrea Fraboni, Vice President & Global Leader of BASES Design Solutions at NielsenIQ. “This year’s winners embody how effective redesigned packaging can help transform and elevate the bottom line of a brand. These companies did it right and we’re excited to showcase their outstanding accomplishments.”
The winners of the 2022 NielsenIQ BASES Design Impact Award* are:
- L’usine Sliced Multigrain Bread (Parent Company: Almarai; Country: Saudi Arabia)
- Coors Light Beer (Parent Company: Molson Coors Beverage Company; Design Agency: Soulsight; Country: United States)
- Brooke's Oros Beverages (Parent Company: Tiger Brands; Design Agency: Just Design; Country: South Africa)
- Cadbury Old Gold Chocolate (Parent Company: Mondelez International; Design Agency: Bulletproof; Country: Australia)
- Lucozade Energy Drink (Parent Company: Suntory; Country: United Kingdom)
- Nescafé Artesano Coffee (Parent Company: Nestlé; Country: Colombia)
- SSENSE Herbal Tea (Parent Company: SSENSE; Design Agency: Pigeon; Country: Canada)
- Turin Chocolate (Parent Company: Mars; Country: Mexico)
- Speed Stick & Lady Speed Stick (Parent Company: Colgate-Palmolive; Design Agency: Dragon Rouge BZ; Country: Mexico)
- Lay's Potato Chips (Parent Company: PepsiCo; Design Agency: PEP Global Design Team; Country: South Africa)
Learn more about our package design research solutions, the NielsenIQ BASES Design Impact Award, and learnings from this year’s winners by visiting the BASES Design Impact Award web page.
*All products and company names are trademarks of their respective holders. No affiliation or endorsement is expressed or implied.
About NielsenIQ
NielsenIQ, a global information services company, delivers the gold standard in consumer and retail measurement, through the most connected, complete, and actionable understanding of the evolving global, omnichannel consumer. NielsenIQ is the source of confidence for the industries we serve and the pioneer defining the next century of consumer and retail measurement. Our data, connected insights, and predictive analytics optimize the performance of CPG and retail companies, bringing them closer to the communities they serve and helping to power their growth.
NielsenIQ, an Advent International portfolio company, has operations in 90+ markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom